Treatment secondary hyperparathyroidoidism in a patient receiving hemodialysis with combination therapy – paricalcitol and cinacalcet
https://doi.org/10.36485/1561-6274-2020-24-6-100-106
Abstract
The article is devoted to the problem of treatment of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD) on renal replacement therapy with programmed hemodialysis. The pathogenesis of VHPT is based on vitamin D deficiency and the associated launch of a cascade of complications of mineral metabolism, which subsequently leads to significant changes in the morphology and density of bone tissue, as well as cardiovascular complications. According to the main clinical guidelines, the goals of treating IHPT in patients with CKD are aimed at preventing the progression of the disease and suppressing the activity of the parathyroid glands by modulating vitamin D receptors and calcium-sensitive receptors. Maintaining the level of parathyroid hormone within the target values improves the quality of life of patients, reduces the incidence of cardiovascular and bone complications. The article presents the result of our own clinical observation on the correction of alfacalcidol-resistant IHPT with hypercalcemia and hyperphosphatemia in a patient on programmed hemodialysis using a combination therapy with a calcimimetic – cinacalcet, colecalciferol and a selective activator of vitamin D receptors – paricalcitol. On the example of a clinical case, the compensation of IHPT, an improvement in the condition of the altered parathyroid glands, bone tissue without the risk of developing hypo-, hypercalcemia and hyperphosphatemia during long-term treatment was demonstrated.
About the Author
L. V. Egshatyan
Endocrinology Research Centre; A.I. Evdokimov Moscow State University of Medicine and Dentistry; Clinical Scientific Center. A.S. Loginova
Russian Federation
Russian Federation
Lilit V. Egshatyan, MD, PhD
117036, Moscow, Dmitriya Ulyanova st., 11
127473, Moscow, Delegatskaya st., 20\1
111123, Moscow, Shosse Enthuziastov, 86
Phone: +7(495)500-00-90
References
1. Bouillon R, Norman AW, Lips PN. Vitamin D deficiency. J Intern Med 2006;260(3):245-254
2. Lips P, Hosking D, Lippuner K et al. The prevalence of vitamin D inadequacy amongst women with osteoporosis: an international epidemiological investigation. J Intern Med 2007;4:408
3. Silva MIB, Cavalieri VV, Lemos CC et al. Body adiposity predictors of vitamin D status in nondialyzed patients with chronic kidney disease: A cross-sectional analysis in a tropical climate city. Nutrition 2017;33:240-247. doi: 10.1016/j.nut.2016.06.012
4. Ye JJ, Zhou TB, Zhang YF et al. Levels of vitamin D receptor and CYP24A1 in patients with end-stage renal disease. Afr Health Sci 2016;16(2):462-467
5. Guideline Update: what’s changed and why it matters Executive summary of the 2017 KDIGO Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD). Kidney International 2017;92:26-36
6. Andress DL. Vitamin D treatment in chronic kidney disease. Semin Dial 2005;18:315-321. doi: 10.1111/j.1525-139X.2005.18408.x
7. Autier P, Gandini S. Vitamin D supplementation and total mortality: a meta-analysis of randomized controlled trials. Arch Intern Med 2007;167:1730-1737. doi: 10.1001/archinte.167.16.1730
8. Christakos S, Lieben L, Masuyama R, Carmeliet G. Vitamin D endocrine system and the intestine. Bone Key Reports 2014;3:496. doi: 10.1038/bonekey.2013.230
9. Friedman PA. Calcium transport in the kidney. Current Opinion in Nephrology & Hypertension 1999;8(5):589-595
10. Cozzolino M, DDusso A, Slatopolsky E. Role of calcium phosphate product and bone associated proteins on vascular calcification in renal failure. J Am Soc Nephrol 2001;12:2511-2516
11. Brown AJ, Finch J, Slatopolsky E. Differential effects of 19-nor-1,25-dihydroxyvitamin D(2) and 1,25-dihydroxyvitamin D(3) on intestinal calcium andphosphate transport. J Lab Clin Med 2002;139(5):279-284
12. Kidney Disease: Improving Global Outcomes (KDIGO). Clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease–mineral and bone disorder (CKD-MBD). Kidney Int 2017;Suppl. 7:1-59
13. Zawierucha J, Malyszko J, Malyszko JS et al. Three Therapeutic Strategies: Cinacalcet, Paricalcitol or Both in Secondary Hyperparathyroidism Treatment in Hemodialysed Patients During 1-Year Observational Study – A Comparison. Front Endocrinol 2019;10(40):1-8. doi: 10.3389/fendo.2019.00040
14. Wolf M, Shah A, Gutierrez O et al. Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int 2007;72:1004-1013. doi: 10.1038/sj.ki.5002451
15. Silver J, Sela SB, Naveh-Many T. Regulation of parathyroid cell proliferation. Curr Opin Nephrol Hypertens 1997;6:321-326
16. Block GA, Martin KJ, de Francisco AL et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl JMed 2004;350:1516-1525
17. Block GA, Zeig S, Sugihara J et al. Combined therapy with cinacalcet and low doses ofvitamin D sterols in patients with moderate to severe secondary hyperparathyroidism. Nephrol Dial Transplant 2008;23:2311-2318
18. Fishbane S, Shapiro WB, Corry DB et al. Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: the ACHIEVE study results. Clin J Am Soc Nephrol 2008;3:1718-1725
19. Lund RJ, Andress DL, Amdahl M et al. Differential effects of paricalcitol and calcitriol on intestinal calcium absorption in hemodialysis patients. Am J Nephrol 2010;31:165-170. doi: 10.1159/000266204
20. Martin KJ, Gonzalez EA, Gellens M et al. 19-Nor-1-alpha25-dihydroxyvitamin D2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. J Am Soc Nephrol 1998;9:1427-1432
21. Ross EA, Tian J, Abboud H et al. Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis. Am J Nephrol 2008;28:97-106. doi: 10.1159/000109398
22. Malluche H, Goldstein D, Massry S. Osteomalacia and hyperparathyroid bone disease in patients with nephrotic syndrome. J Clin Invest 1979;63:494-500
23. Zheng JQ, Hou Y-C, Zheng C-M et al. Cholecalciferol Additively Reduces Serum Parathyroid Hormone and Increases Vitamin D and Cathelicidin Levels in Paricalcitol-Treated Secondary Hyperparathyroid Hemodialysis Patients. Nutrients 2016;8(11):708. doi: 10.3390/nu8110708
24. Egshatyan LV, Mokrisheva NG. The effectiveness of nutritional vitamin d supplementation and selective vitamin d receptor agonists treatment on secondary hyperparathyroidism in chronic kidney diseases patients. Osteoporosis and Osteopathy 2018;21(2):12-22
25. Meola M, Petrucci I, Barsotti G. Long-term treatment with cinacalcet and conventional therapy reduces parathyroid hyperplasia in severe secondary hyperparathyroidism. Nephrol Dial Transplant 2009;24:982-989. doi: 10.1093/ndt/gfn654
26. Szabo A, Merke J, Beier E et al. 1,25(OH)2vitamin D3 inhibits parathyroid cell proliferation in experimental uremia. Kindey Int 1989;35:1049-1056
27. Denda M, Finch J, Brown AJ et al. 1,25-Dihydroxyvitamin D3 and 22-oxacalcitriol prevent the decrease in vitamin D receptor content in the parathyroid glands of uremic rats. Kidney Int 1996;50:34-39
28. Martin KJ, Gonzalez EA. Metabolic bone disease in chronic kidney disease. J Am Soc Nephrol 2007;18:875-885. doi: 10.1681/ASN.2006070771
29. Jacome-Galarza CE, Lee SK, Lorenzo JA et al. Parathyroid hormone regulates the distribution and osteoclastogenic potential of hematopoietic pro-genitors in the bone marrow. J Bone Miner Res 2011;26:1207-1216
30. Kalantar-Zadeh K, Shah A, Duong U et al. Kidney bone disease and mortality in CKD: revisiting the role of vitamin D, calcimimetics, alkaline phosphatase, and minerals. Kidney Int Suppl 2010;117:S10-S21. doi: 10.1038/ki.2010.189
31. Nybo M, Jespersen B, Aarup M et al. Determinants of bone mineral density in patients on haemodialysis or peritoneal dialysis – a cross-sectional, longitudinal study. Biochemia 2013;23(3):342-350
32. Souberbielle JC, Cheriet S, Cavalier E. Distinctive Aspects of Laboratory Testing to Evaluate Mineral and Bone Metabolism in Patients with Chronic Kidney Disease. Joint Bone Spine 2012;79:S99S103. doi: 10.1016/S1297-319X(12)70016-7
33. Malluche H, Monier-Faugere M, Wang G et al. An assessment of cinacalcet HCl effects on bone histology in dialysis patients with secondary hyperparathyroidism. Clin Neph 2008;69:269-278. doi: 10.5414/cnp69269
34. Hruska KA, Teitelbaum S. New features of renal osteodystrophy. N Engl J Med 1995;333:166-174
35. Slatopolsky E, Cozzolino M, Lu Y et al. Efficacy of 19-Nor1,25-(OH)2D2 in the prevention and treatment of hyperparathyroid bone disease in experimental uremia. Kid Int 2003;63:2020-2027. doi: 10.1046/j.1523-1755.2003.00029.x
36. Riccio E, Sabbatini M, Bruzzese D et al. Effect of Paricalcitol vs Calcitriol on Hemoglobin Levels in Chronic Kidney Disease Patients: A Randomized Trial. PLOS ONE 2015;17;10(3):e0118174. doi: 10.1371/journal.pone.0118174
37. Kong J, Kim GH, Wei M et al. Therapeutic Effects of Vitamin D Analogs on Cardiac Hypertrophy in Spontaneously Hypertensive Rats. Am J Pathol 2010;177(2):622-631. doi: 10.2353/ajpath.2010.091292
38. Zoccali C, Curatola G, Panuccio V et al. Paricalcitol and Endothelial Function in Chronic Kidney Disease Trial. Hypertension. 2014;64(5):1005-1011. doi: 10.1161/HYPERTENSIONAHA.114.03748
39. Zheng Y, Zhu J, Zhou M et al. Meta-analysis of longterm vitamin D supplementation on overall mortality. PLoS ONE 2013;8(12):e82109. doi: 10.1371/journal.pone.0082109
Review
For citations:
Egshatyan L.V. Treatment secondary hyperparathyroidoidism in a patient receiving hemodialysis with combination therapy – paricalcitol and cinacalcet. Nephrology (Saint-Petersburg). 2020;24(6):100-106. (In Russ.) https://doi.org/10.36485/1561-6274-2020-24-6-100-106
Views:
511
Email this article 